01-a-”Oı€™JŠY-4.02

Size: px
Start display at page:

Download "01-a-”Oı€™JŠY-4.02"

Transcription

1 Apr. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 1 ) Fosfomycin b fosfomycin (FOM) FOM b- (cefazolin (CEZ), cefotiam (CTM), cefmetazole (CMZ) piperacillin (PIPC)) b - AmpC b- FOM glucose-6-phosphate (G6P) Mueller-Hinton agar (MHA) MHA G6P nutrient agar (NA) NA FOM G6P G6P b - 2 G6P Mueller- Hinton broth Escherichia coli, Pseudomonas aeruginosa FOM 4 MIC 2 P. aeruginosa Staphylococcus aureus 1/100 P. aeruginosa PAO1 Enterobacter cloacae ATCC13047 AmpC b - FOM 1/25 1/65 b- b - MIC FOM b - MIC b - MIC P. aeruginosa MexAB-OprM, MexCD-OprJ, MexXY/OprM MexEF-OprN

2 106( 2 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 Apr. FOM b- MexAB-OprM MexCD-OprJ FOM AmpC Fosfomycin (FOM) 1) 2) 20 FOM b - 3) FOM 4) FOM FOM 2 sn- -3- (G3P transport system: GlpT system) 5) (sugar phosphate transport system: UhpT system) 6) glucose-6-phosphate (G6P) G6P 7) FOM G6P 8) in vivo in vitro 1975 FOM MIC nutrient agar (NA) FOM 1) NCCLS UhpT system FOM (Mueller- Hinton agar: MHA) G6P 9,10) 11 14) FOM MIC ATCC FOM MIC 4 MIC (MHA) NCCLS (G6P MHA) FOM (NA) FOM NCCLS G6P NA b - FOM AmpC b -

3 Apr. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 3 ) b - MIC FOM I. 1 FOM cefazolin CEZ cefotiam CTM cefmetazole CMZ piperacillin PIPC FOM CEZ CTM CMZ PIPC ) b - Staphylococcus aureus, S. epidermidis, Streptococcus pyogenes, S. pneumoniae, Enterococcus faecalis, E. faecium, E. hirae, Micrococcus luteus Escherichia coli, Citrobacter freundii Salmonella typhimurium, Shigella flexneri, Klebsiella oxytoca, K. pneumoniae, Enterobacter cloacae E. aerogenes, Serratia marcescens, Proteus mirabilis, P. vulgaris, Morganella morganii, Providencia rettgeri Pseudomonas aeruginosa, Haemophilus influenzae, Burkholderia cepacia Stenotrophomonas maltophilia Acinetobacter calcoaceticus Alcaligenes xylosoxidans A. faecalis, Neisseria gonorrhoeae, N. meningitidis Moraxella catarrhalis Peptostreptococcus anaerobius, Clostridium histolyticum, Finegoldia magna, Collinsella aerofaciens Eggerthella lenta Bacteroides fragilis, B. ovatus, B. thetaiotaomicron, Prevotella bivia, Fusobacterium varium b- S. aureus 15), E. coli 16,17), H. influenzae P. aeruginosa 18) blaz, TEM-1 Toho-1, IMP-1, AmpC, ROB-1 b - isogenic 8 12 P. aeruginosa PAO1 isogenic MexAB-OprM, MexCD-OprJ, MexXY/OprM MexEF-OprN OprD 19) isogenic ampc 3 (MIC) 20) MIC 1) 25 m g/ml G6P (Sigma) MIC 37 C Mueller-Hinton broth (MHB, Difco) 10 6 CFU/mL Mueller- Hinton agar (MHA Difco) ( ) MIC MIC ( ) 37 C 1000 NA (Difco) MIC S. pyogenes, S. pneumoniae, M. catarrhalis MIC 5% MHA Neisseria H. influenzae MHA 5%

4 108( 4 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 Apr. MHB McFarland Proteus P. rettgeri M. morganii MHB NB 3.5% Bacto Agar (Difco) GAM ( ) GAM ( ) MIC MIC S. aureus ATCC 29213, S. aureus FDA 209P JC-1, S. pneumoniae ATCC 49619, E. coli ATCC 25922, E. coli NIHJ JC-2, B. thetaiotaomicron ATCC AmpC b - P. aeruginosa PAO1 E. cloacae ATCC MHA MHB 37 C MHB 20 3 FOM 1, 3, 10, 30, 100 mg/ml 3 CEZ, CTM, CMZ 1, 10, 100 mg/ml, PIPC 0.1, 1, 10 m g/ml (5,600 g, 10 minutes, 4 C) 1/15 M (ph 7.0) b - 80 C 1 ml 1/15 M (ph 7.0) (11,500 g, 60 minutes, 4 C) b - b- cephalothin (CET, Sigma) UV 21) 1 1 mmol 1 unit (unit/mg protein) DC (BioLad) b- 3 mean S.D. 0.1 m g/ml imipenem IPM E. cloacae ATCC S. aureus ATCC MHA G6P FOM MIC: 1 m g/ml E. coli ATCC m g/ml MHB 10 5 CFU/mL MHB 37 C 2 1/2, 1, 4, 16, 64 MIC FOM 25 mg/ml G6P 1, 2, 4, 6 (CFU/mL) P. aeruginosa MSC mg/ml 2 1/2, 1, 4, 16 MIC FOM 25 m g/ml G6P 6. P. aeruginosa MSC MIC FOM G6P % 1% Spurr EM (TEM; JEM-2000EXII, JEOL) t- (JFD-300, JEOL) (SEM; JSM-6340F, JEOL) 22)

5 Apr. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 5 ) II. 1 MIC 4 FOM MIC Tables 1, 2 MHA G6P NA G6P FOM 2 4 (Table 1) MHA G6P NA G6P FOM (Table 2) FOM (8 256 ) Proteus G6P FOM G6P (Table 3) b - FOM G6P (data not shown) 2 FOM FOM S. aureus ATCC /100 (Fig. 1A) E. coli ATCC MIC 6 16 MIC 2 (Fig. 1B) P. aeruginosa MSC-996 (Fig. 1C) 3 P. aeruginosa FOM 2 P. aeruginosa MSC- 996 SEM (Fig. 2A) (Fig. 2B, C) FOM 4 (Fig. 2D, E) FOM 2 TEM (Fig. 3A) FOM (Fig. 3B, C) FOM 4 (Fig. 3D, E) 4 AmpC b- P. aeruginosa PAO1 E. cloacae ATCC AmpC b , unit/mg protein P. aeruginosa PAO1 FOM PIPC b - b - CMZ CTM CEZ (Fig. 4A) E. cloacae ATCC b - FOM PIPC 2.0, 2.8 (Fig. 4B) 0.1 m g/ml IPM unit/mg protein b- 5 b- E. coli c 1037 b - b - MIC FOM MIC b - MIC NA G6P MIC (Table 4) S. aureus H. influenzae P. aeruginosa b -

6 110( 6 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 Apr. Table 1. Drug susceptibility of aerobic Gram-positive bacteria of standard strains.

7 Apr. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 7 ) Table 2. Drug susceptibility of aerobic Gram-negative bacteria of standard strains.

8 112( 8 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 Apr. Table 3. Drug susceptibility of anaerobic bacteria of standard strains.

9 Apr. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 9 ) Fig. 1. Bactericidal activity of FOM against S. aureus ATCC (A) (MIC of FOM: 1 m g/ml), E. coli ATCC (B) (MIC: 1 m g/ml), and P. aeruginosa MSC-996 (C) (MIC: 32 mg/ml). : control; : 1/2 MIC; : 1 MIC; : 4 MIC; : 16 MIC; : 64 MIC. b - NA G6P FOM MHA 1024 (K. oxytoca GN10650) FOM MIC b- ampc (KG5002, 5004, 5008) MIC b- MexAB-OprM MexCD-OprJ III. 6 P. aeruginosa PAO1 MexAB-OprM, MexCD- OprJ MexXY/OprM FOM MIC PAO1 (Table 5) P. aeruginosa PAO4222 MexEF-OprN KG4001 FOM MIC PAO4222 (MHA 128 m g/ml) FOM MexEF-OprN (data not shown) isogenic ampc FOM AmpC b - FOM ,23) 2003 FOM fosfomycin tromethamine 24) 25) FOM FOM UDP- GlcNAc 3) FOM G6P FOM

10 114( 10 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 Apr. Fig. 2. Scanning electron micrographs illustrating morphological changes in P. aeruginosa MSC-996 after treatment with FOM at four times the MIC. A: control; B and C: 2 hours after treatment; D and E: 4 hours after treatment. Bars indicate 200 nm. FOM MIC 5 mg/ml G6P S. aureus, E.coli, Shigella MIC 1) TSUBOI 40 G6P m g/ml 8) NCCLS G6P (25 mg/ml) 9) FOM NA G6P MIC 2 (B. cepacia, A. xylosoxidans) 32 mg/ml MHA MIC in vivo 26) MHA MIC in vivo 27) FOM (BP) MHA 25mg/mL G6P 64 mg/ml 28) FOM

11 Apr. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 11 ) Fig. 3. Transmission electron micrographs illustrating morphological changes in P. aeruginosa MSC-996 after treatment with FOM at four times the MIC. A: control; B and C: 2 hours after treatment; D and E: 4 hours after treatment. Bars indicate 200 nm. MIC BP 4 FOM MIC 4 BP BP FOM BARRY A. fosfomycin tromethamine E. coli, Citrobacter spp., Klebsiella spp., Enterobacter spp. G6P 29) Staphylococcus spp. Enterococcus spp. Pseudomonas spp. S. marcescens G6P FOM 4 G6P b -

12 116( 12 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 Apr. Fig. 4. AmpC b -lactamase expression in P. aeruginosa PAO1 (A) and E. cloacae ATCC (B) induced by FOM, CEZ, CTM, CMZ, and PIPC. Data were expressed as mean S.D. of three independent experiments. : FOM; : CEZ; : CTM; : CMZ; : PIPC. P. aeruginosa PAO1 E. cloacae ATCC13047 AmpC b- FOM 2 REGUERA J.A. b - cefoxitin 12.5 b - FOM ,31) b- b - FOM (GlpT UhpT ) (mura ) FOM ( fosa fosb fosc) 23) 4 MexAB-OprM MexCD-OprJ MexXY/OprM MexEF-OprN 19) FOM FOM MIC b - MexAB-OprM MexCD-OprJ 32) b- 33) 1980

13 Apr. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 13 ) Table 4. Drug susceptibility of isogenic mutants carrying b-lactamase coded plasmid and clinical isolates.

14 118( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 Apr. Table 5. Drug susceptibility of isogenic efflux mutants of P. aeruginosa PAO1.

15 Apr. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 15 ) MRSA 1999 (Centers for Disease Control and Prevention: CDC) surgical site infection (SSI) 13) Class II/Clean-Contaminated operation Class I/Clean operation 11,12) ampicillin (ABPC) CEZ FOM FOM CMZ flomoxef b - FOM clindamycin FOM S. aureus, E. coli, K. pneumoniae, Proteus spp. Enterococcus spp., P. aeruginosa Bacteroides. spp ) 5 FOM 1g ) 11) 35) FOM 1 g , mg/ml 34) 5 36) G6P 3 FOM MIC 100, 230 FOM 0.56% FOM 3 FOM 5 (0.005%) 2) E. coli CEZ MIC 128 m g/ml 37) 38) 11) FOM FOM MIC b - b - FOM b -

16 120( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 Apr. FOM 1) Fosfomycin in vitro, in vivo Chemotherapy 23: , ) fosfomycin sodium 10 prospective 48: , ) KAHAN, F. M.; J. S. KAHAN, P. J. CASSODY, et al.: The mechanism of action of fosfomycin (phosphonomycin). Ann. N.Y. Acad. Sci. 235: , ) Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Fosfomycin Jpn. J. Antibiotics 48: , ) KOCH, J. P.; S. HAYASHI & E. C. C. LIN: The control of dissimilation of glycerol and L-a -glycerophosphate in Escherichia coli. J. Biol. Chem. 239: , ) WESTON, L. A. & R. J. KADNER: Identification of Uhp polypeptides and evidence for their role in exogenous induction of the sugar phosphate transport system of Escherichia coli K-12. J. Bacteriol. 169: , ) WINKLER, H. H.: Compartmentation in the induction of the hexose-6-phosphate transport system of Escherichia coli. J. Bacteriol. 101: , ) TSUBOI, I.; H. IDA, E. YOSHIKAWA, et al.: Antibiotic susceptibility of enterohemorrhagic Eschericia coli O157:H7 isolated from an outbreak in Japan in Antimicrob. Agents Chemother. 42: , ) National Committee for Clinical Laboratory Standards. : Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard M7- A5. National Committee for Clinical Laboratory Standards, Wayne PA., ) ANDREWS, J. M.; F. BAQUERO, J. M. BELTRAN, et al.: International collaborative study on standardization of bacterial sensitivity to fosfomycin. J. Antimicrob. Chemother. 12: , )Jpn. J. Antibiotics 57: 11 32, ) 49 (S-B): 71 89, ) MANGRAM, A. J.; T. C. HORAN, M. L. PEARSON, et al.: Guideline for prevention of surgical site infection. Infect. Control Hosp. Epidemiol. 20: , ) (1997 ) 45: , ) SHALITA, Z.; E. MURPHY & R. P. NOVICK: Penicillinase plasmids of Staphylococcus aureus: structural and evolutionary relationships. Plasmid 3: , ) ISHII, Y.; A. OHNO, H. TAGUCHI, et al.: Cloning and sequence of the gene encoding a cefotaxime-hydrolyzing class A beta-lactamase isolated from Escherichia coli. Antimicrob. Agents Chemother. 39: , ) KUGA, A.; R. OKAMOTO & M. INOUE: ampr gene mutations that greatly increase class C beta-lactamase activity in Enterobacter cloacae. Antimicrob. Agents Chemother. 44: , ) IYOBE, S.; M. TSUNODA & S. MITSUHASHI: Clonig and expression in Enterobacteriaceae of the extende-spectrum beta-lactamase gene from a Pseudomonas aeruginosa plasmid. FEMS Microbiol. Lett. 121: , ) OKAMOTO, K.; N. GOTOH & T. NISHINO: Alterations of susceptibility of Pseudomonas aeruginosa by overproduction of multidrug efflux systems, MexAB-OprM, MexCD-OprJ, and MexXY/OprM to carbapenems: substarte specificities of the efflux systems. J. Infect. Chemother. 8: , ) MIC Chemotherapy 29: 76 79, ) WALEY, S. G.: A spectrophotometric assay of betalactamase action on penicillins. Biochem. J. 139: , ) YAMADA, S.; M, SUGAI, H. KOMATSUZAWA, et al.: An auto lysin ring associated with cell separation of Staphylococcus aureus. J. Bacteriol. 178: , ) Fosfomycin 47: , ) BELLA, D. D. & V. FERRARI: Monuril: historical background. In New Trends in Urinary Tract Infections. Int. Symp., Rome 1987 (NEU H.C., WILLIAMS J.D. ed.), pp , Karger, Basel, ) SCHITO, G. C.: Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int. J. Antimicrob. Agents 22 (S-2): 79 83, ) HAGG, R.; W. VOMEL & W. SCHAUMANN: Comparioson of in vitro methods for the determination of the activity of fosfomycin with the efficacy determined in experimentally infected mice. Immun. Infekt. 9: , ) INOUE, S.; T. WATANABE, T. TSURUOKA, et al.: An increase in the antimicrobial activity in vitro of fosfomycin under

17 Apr. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 17 ) anaerobic condition. J. Antimicrob. Chemother. 24: , ) GILBERT, D. N.; R. C. MOELLERING, Jr., G. M. ELIOPOULOS, et al.: The Sanford Guide to Antimicrobial Therapy 34 th edition, 2004, Antimicrobiology Therapy, Inc. Hyde Park, Vt, USA 29) BARRY, A. & P. C. FUSHS: In vitro susceptibility testing procedures for fosfomycin tromethamine. Antimicrob. Agents Chemother. 35: , ) REGUERA, J. A.; F. BAQUERO, J. BERENGUER, et al.: b -Lactam-fosfomycin antagonism involving modification of penicillin-binding protein 3 in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 34: , ) SUN, D.; S. COHUN, N. MANI, et al.: A pathway-specific cell based screening system to detect bacterial cell wall inhibitors. J. Antibiotics 55: , ) MASUDA, N.; E. SAKAGAWA, S. OHYA, et al.: Substrate specifities of MexAB-OprM, MexCD-OprJ, and MexXY- OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44: , ) NAKAE, T.; A. NAKAJIMA, T. ONO, et al.: Resistance to b -lactam antibiotics in Pseudomonas aeruginosa due to interplay between the MexAB-OprM efflux pump and b -lactamase. Antimicrob. Agents Chemother. 43: , ) Fosfomycin-Na Jpn. J. Antibiotics 31: , ) OHGE, H.; Y. TAKESUE, T. YOKOYAMA, et al.: An additional dose of cefazolin for intraoperative prophylaxis. Surg. Today 29: , )Fosfomycin ( ) Chemotherapy 23: , ) 2002 Jpn. J. Antibiotics 57: 33 69, ) 27: , 1994 ANTIMICROBIAL ACTIVITY OF FOSFOMYCIN UNDER VARIOUS CONDITIONS AGAINST STANDARD STRAINS, b -LACTAM RESISTANT STRAINS, AND MULTIDRUG EFFLUX SYSTEM MUTANTS TAKESHI MIKUNIYA, TORU HIRAISHI, KAZUNORI MAEBASHI, TAKASHI IDA, TOSHIHIKO TAKATA and MUNEO HIKIDA Infectious Disease Research Laboratories, Meiji Seika Kaisha, LTD., 760 Morooka-cho, Kohoku-ku, Yokohama , Japan SAKUO YAMADA Department of Microbiology, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama , Japan NAOMASA GOTOH and TAKESHI NISHINO Department of Microbiology, Kyoto Pharmaceutical University, 5 Misasaginakauchi-cho, Yamashina-ku, Kyoto , Japan The purpose of this study was to evaluate the possible benefit of fosfomycin (FOM) as prophylactic antibiotic in terms of antimicrobial activity and the potential of inducibility of b -lactamase, compared with cefazolin, cefotiam, cefmetazole, and piperacillin that are commonly used as perioperative agents. The in vitro activity of FOM against aerobic Gram-negative bacteria using Mueller-Hinton agar or nutrient agar supplemented with glu-

18 122( 18 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 Apr. cose-6-phosphate (G6P) as tested medium increased within a range from 2 to 256 times the activity in the medium without G6P. However, the susceptibility of Gram-positive bacteria to FOM remained largely unchanged with or without G6P. There was no aerobic- or anaerobic-bacteria which changed susceptibility against b -lactam antibiotics under various tested medium conditions. FOM demonstrated strong bactericidal activity against Escherichia coli and Pseudomonas aeruginosa in a dose dependent manner, and decreased viable cell counts of Staphylococcus aureus. In the case of P. aeruginosa, transmission electron micrographs study revealed that numerous lysed cells were present 2 hours after treatment with FOM at four times the MIC. First and second generation cephalosporins induced AmpC-type b -lactamase in a dose dependent manner among b -lactamase inducible strains of P. aeruginosa and Enterobacter cloacae. On the other hand, inducible activity of FOM on b -lactamase production was less than 1/25 to 1/65 compared with those of cephalosporins. In addition, FOM maintained strong antimicrobial activity for over then 20 years after marketing, because of the excellent stability against various types of b -lactamase produced by plasmid-carrying bacteria and clinical isolates. FOM was not extruded by four types of efflux systems, such as MexAB-OprM, MexCD-OprJ, MexXY/ OprM and MexEF-OprN, however b -lactam antibiotics were substrates of MexAB-OprM and MexCD-OprJ. In conclusion, FOM provides adequate coverage for both aerobic Gram-positive and Gram-negative bacteria causing postoperative infections. Further, FOM would not select/concentrate b -lactamase producing bacteria in the clinical fields and would not be a substrate for multidrug efflux system of P. aeruginosa.

CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc

CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marcescens P. aeruginosa P. aeruginosa Streptococcus pyogenes Streptococcus

More information

Fig.1 Chemical structure of BAY o 9867

Fig.1 Chemical structure of BAY o 9867 Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985

More information

1.Streptococcus pneumoniae, Streptococcus pyogenes JC-1,S.aureus Smith,methicillin (DMPPC)- susceptible S. aureus subsp. aureus (MSSA) TR101, DMPPC-resistant S. aureus subsp. aureus (MRSA) TR102, Staphylococcus

More information

CHEMOTHERAPY OCT. 1994 Tazobactam Piperacillin Fig. I. Chemical structures of tazobactam and piperacillin. Table 1. Media used for preculture and MIC determination BHIB: Brain heart infusion broth (Difco),

More information

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.); VOL.35 S-2 CHEMOTHERAPY Fig.1 Chemical structure of carumonam CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical

More information

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,

More information

VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia

VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia ceftazidime, cefpirome, cefepime, cefoperazone/sulbactam (2: 1), imipenem Staphylococcus aureus oxacillin coagulase negative staphylococci Escherichia coli piperacillin Klebsiellac spp. Citrobacter Pseudomonas

More information

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69

More information

日本化学療法学会雑誌第61巻第6号

日本化学療法学会雑誌第61巻第6号 β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae

More information

CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str

CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str cefaclor(ccl),cefuroxime(cxm),cefixime (CFIX),cefteram(CFTM),cefdinir(CFDN) pneumoniae,streptococcus pyogenes Moraxella catarrhalis,haemophilus influenzae,escherichia coli, Klebsiella pneumoniae,proteus

More information

CHEMO THE RAPY OCT. 1994

CHEMO THE RAPY OCT. 1994 bilis (0.78), Proteus vulgaris (1.56), Enterococcus faecalis (3.13), Staphylococcus epidermidis (6.25), Klebsiella pneumoniae (6.25), Morganella morganii (6.25), Escherichia coli (12.5), Providencia rettgeri

More information

Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil

More information

日本化学療法学会雑誌第64巻第4号

日本化学療法学会雑誌第64巻第4号 β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterobacter spp., Serratia spp., Burkholderia cepacia, Flavobacterium spp., Alcaligenes spp. THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium

More information

Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis

Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis, E.coil,Klebsiella pneumoniae,klebsiella oxytoca,proteus

More information

Table 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,

More information

CHEMOTHERAPY

CHEMOTHERAPY CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 243 ( 37 ) 2007 12 2008 5 19 863 methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof

THE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 243 ( 37 ) 2007 12 2008 5 19 863 methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof 242 ( 36 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 prulifloxacin * ** ** CMC * ** 2010 2 22 Prulifloxacin ulifloxacin (UFX) 3 1 2003 12 2004 5 19 534 2 2005 12 2006 5 19 805 3 THE JAPANESE JOURNAL OF

More information

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,

More information

Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis

Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis Staphylococcus aureus S. aureus (MRSA) vancomycin (VCM), arbekacin (ABK) Streptococcus pneumoniae cefuzonam (CZON), cefpirome (CPR) S. pneumoniae Enterococcus faecalis ampicillin (ABPC), imipenem (IPM)

More information

Table 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against

More information

Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates

More information

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,

More information

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in

More information

1272 CHEMOTHERAPY MAR. 1975

1272 CHEMOTHERAPY MAR. 1975 1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides

More information

CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk

CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp, CHEMOTHERAPY DEC. 1982 Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus,

More information

b) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates

More information

VOL.30 NO.12 CHEMOTHERAPY Fig. 1 Effect of temperature on the growth curve of A. calcoaceticus A. calcoaceticits Ac 54 A. calcoacetictts Ac 164 Fig. 2 Effect of medium ph on the growth curve of A. calcoaceticus

More information

VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC

VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC, E. coli NIHJ JC-2 pneumoniae E. coli 106, K. pneumoniae

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 33( 33 ) 2002 JA * 1 * 2 2003 12 15 * 1) * 2) 34( 34 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 1982 7 2002 (2002.4 2003.3) 1 174 131 (75.3%) 334 171 163 Staphylococcus

More information

Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 11( 11 ) 2003 12 17 (MRSA) penicillin-resistant Streptococcus pneumoniae (PRSP) 3 I. 12( 12 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 3 1997 1) (1985)

More information

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of

More information

02-(a)-Łi’ì™·Łv-4.11

02-(a)-Łi’ì™·Łv-4.11 THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 105( 13 ) 2001 1) 2) 3) JA 2 7 1) 2) 3) 106( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. 1982 7 2001 (2001.4 2002.3) 1 221 175 (79.2%) 420 186 234 Staphylococcus

More information

CHEMOTHERAPY

CHEMOTHERAPY CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY

More information

Table 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains

More information

Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.

More information

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella

More information

Table 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and

More information

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT

More information

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative

More information

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration

More information

988 CHEMOTHERAPY NOV. 1971

988 CHEMOTHERAPY NOV. 1971 988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical

More information

CHEMOTHERAPY

CHEMOTHERAPY CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity

More information

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter

More information

ヒビスコール液A カタログ

ヒビスコール液A カタログ 1 2 3 2002 10 Centers for Disease Control and Prevention CDC A 1. 2. 0.2% 3. 1 A 2 3 4 5 6 7 1 1 1. 2. 3. 2 1. 1 0.2% 10 Pseudomonas aeruginosa ATCC 27853 20 20 Proteus vulgaris ATCC 13315 30 20 Escherichia

More information

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega 1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity

More information

Fig. 1 Chemical structure of DL-8280

Fig. 1 Chemical structure of DL-8280 Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.

More information

CHEMOTHERAPY NOV Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aur

CHEMOTHERAPY NOV Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aur CHEMOTHERAPY NOV. 1985 Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aureus Streptococcus pyogenes Escherichia coli Klebsiella

More information

366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -

366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli - Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486

More information

CHEMOTHERAPY JUNE 1986

CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Fig. 1 Structural formula of L-105 CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Table 1 Antibacterial spectra of L-105 against gram negative anaerobic rods Inoculum 106 cells/ml

More information

日本化学療法学会雑誌第53巻第S-1号

日本化学療法学会雑誌第53巻第S-1号 Doripenem in vitro Doripenem in vitro 7 7 3 DRPM in vitro DRPM 00 DRPM Staphylococcus Streptococcus µ gml MIC90 Moraxella catarrhalishaemophilus influenzae µ gml MIC90 imipenem IPM panipenem meropenemmepm

More information

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P. pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P. aeruginosa 30, P. maltophilia pyogenes 32, Escherichia

More information

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak

More information

70( 70 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Meropenem 2002 * * * * * * * * * * * * * * * * * * * * * * NTT Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 71( 71 ) * * * * 2003 12 22 Meropenem

More information

Table 1. Antimicrobial drugs using for MIC

Table 1. Antimicrobial drugs using for MIC Table 1. Antimicrobial drugs using for MIC Table 2. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive eategory for Staphylococcus aureus Table 3. Interpretive

More information

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,

More information

R06_01

R06_01 Staphylococcus aureus (MSSA) PCG (N=118,334) 57,369 (48.5%) 判定不能 :3 (0.0%) 60,962 (51.5%) CEZ (N=143,723) I:42 (0.0%) 143,635 (99.9%) R:46 (0.0%) CVA/AMPC (N=19,281) R:14 (0.1%) 19,265 (99.9%) 判定不能 :2

More information

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine

More information

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table

More information

CHEMOTHERAPY MAY 1988 Table 1 Media used for preculture and MIC determination *BHIB: Brain heart infusion broth (Difco), B-NAD: B-Nicotinamide adenine dinucleotide (Sigma chemical Co.), GAMB GAM broth

More information

日本化学療法学会雑誌第53巻第S-3号

日本化学療法学会雑誌第53巻第S-3号 moxifloxacin in vitro moxifloxacin in vitro 17 9 6 17 11 21 moxifloxacinmflx in vitro cefdinir CFDNclavulanic acidamoxicillincvaampcclarithromycincamclindamycincldm levofloxacinlvfx 1MFLX Clostridium clostridiiformeclostridium

More information

2 CHEMOTHERAPY JAN. 1976 VOL. 24 NO. 1 CHEMOTHERAPY 3 Table 1 Antibacterial spectra of Cephacetrile, Cephalothin, Cephaloridine and Cefazolin 4 CHEMOTHERAPY JAN. 1976 Fig. 1 In vitro activity of Cephacetrile,

More information

PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC= Piperacillin

PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC= Piperacillin Key words : Clinical isolates, Antibacterial susceptibility, Scale of hospital PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC=

More information

Fig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic

More information

CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali

CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali CHEMOTHERAPY DEC. 1988 (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis Pseudomonas aeruginosa, Serratia ma- Fig. 1. Chemical

More information

03-b-„FŒ{›xŒ¾-4.02

03-b-„FŒ{›xŒ¾-4.02 518( 30 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 1. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 519( 31 ) 9 5 2003 8 2004 7 14 565 701 258 (36.8%) 443 (63.2%) Staphylococcus aureus

More information

CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table

More information

VOL.30 NO.10 CHEMOTHERAPY 1123 Fig,1 Group B case 6 hepatolithiasis,e.k.66 y.0.,f.45kg Postoperative wound infection Fig.2 Group B case 15 gastric cancer,k.k.60 y.o.,m. Postoperative peritonitis Fig.3

More information

CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)

CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330) CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Fig. 2 Comparison of standard curves of CTT on various test organisms by cylinder plate method Column

More information

CHEMOTHERAPY 52 MAY d a a. Normal S. aureus d Đg/ml, 2h; e b b Đg/ml, Abnormal e. division lh; Abnormal thickening division cross f c. 1

CHEMOTHERAPY 52 MAY d a a. Normal S. aureus d Đg/ml, 2h; e b b Đg/ml, Abnormal e. division lh; Abnormal thickening division cross f c. 1 Levloxacin V.:1 Z iiiir fa L CHEMOTHERAPY 52 MAY d a a. Normal S. aureus d. 0.39 Đg/ml, 2h; e b b. 0.10 Đg/ml, Abnormal e. division lh; Abnormal thickening division cross f c. 1992 0.39 Đg/ml, and Fig.

More information

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.

More information

VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,

More information

2.7 臨床概要

2.7 臨床概要 2.7 臨床概要 A/G Al-P ALT AST AT- AUC AZM BIPM BP BUN CEZ CFPN-PI CFU CLcr Cmax CNS COPD CPFX CRP CS CYP CVA DBT DHP-I DIC DRPM DRPM-DC FAS γ-gtp GCP GNB GNF-GNR GPB HAM - Staphylococcus C P450 -I Full Analysis

More information

2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 Feb Neisseria gonorrhoeae ceftriaxone CTRX % 2010 CTRX 20 FQ staphylococci, E. faecium, N.

2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 Feb Neisseria gonorrhoeae ceftriaxone CTRX % 2010 CTRX 20 FQ staphylococci, E. faecium, N. Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 1 1 2013 69 11,762 2015 11 16 1994 2013 69 19 11,762 FQ 33 Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae

More information

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii

More information

VOL.32 S-9 CHEMOTHERAPY Table 1 Minimum inhibitory concentrations of AC-1370, CPZ and CAZ Table 2 Efficacy of AC-1370 and CPZ against systemic infections in mice *Inoculum size: 106 cells/ml * 95% confidence

More information

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin

More information

untitled

untitled Seminal paper Anhalt JP Pioneering paper Claydon MA Kishnamurthy T Enterobacter B. cereus Routine identification paper Eigner U Seng P Cherkaoui A Saureus S. Saureus* S. Vagococcus Haemophilus Mycobacterium

More information

Table 1. MICs of fosfomycin and other antibiotics determined by agar dilution method against Pseudomonas aeruginosa FOM: fosfomycin, PIPC: piperacilli

Table 1. MICs of fosfomycin and other antibiotics determined by agar dilution method against Pseudomonas aeruginosa FOM: fosfomycin, PIPC: piperacilli Key words: Pseudomonas aeruginosa, fosfomycin, ofloxacin, Table 1. MICs of fosfomycin and other antibiotics determined by agar dilution method against Pseudomonas aeruginosa FOM: fosfomycin, PIPC: piperacillin,

More information

日本化学療法学会雑誌第59巻第5号

日本化学療法学会雑誌第59巻第5号 Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S.

More information

JUNE 1988

JUNE 1988 JUNE 1988 VOL.36 S-2 CHEMOTHERAPY Table 1. Antibacterial activity of NY-198 against standard strains of bacteria By the agar-dilution method (inoculum: 106 CFU/ml) JUNE 1988 Fig. 3. Antibacterial activity

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon

THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 189 49 1 : 14 1 2 2 3 1 2 3 2015 4 3 1 : 14 CVA/AMPC 1 : 14 27 CVA/AMPC 1 : 14 88.5% Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis

More information

CHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative

More information

VOL.27 S-5 CHEMOTHERAPY Table 1 Clinical evaluations of cefamandole on UTI (1) Benign prostatic hypertrophy (2) Transurethral resection of bladder tum

VOL.27 S-5 CHEMOTHERAPY Table 1 Clinical evaluations of cefamandole on UTI (1) Benign prostatic hypertrophy (2) Transurethral resection of bladder tum CHEMOTHERAPY JUNE 1972 Fig. 1 Chemical structure of cefamandole E. coil, Klebsiella Proteus vulgaris indole positive Proteus sp., Enterobacter, Citrobacter, Serratia marcescens Chemical name: 7-D-mandelamido-3-

More information

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin

More information

Fig. 1 Chemical structure of KW-1070

Fig. 1 Chemical structure of KW-1070 Fig. 1 Chemical structure of KW-1070 Fig. 2 Sensitivity distribution of clinical isolates Fig. 4 Sensitivity distribution of clinical isolates Fig. 3 Sensitivity distribution of clinical isolates Fig.

More information

Oct THE JAPANESE JOURNAL OF ANTIBIOTICS Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, taz

Oct THE JAPANESE JOURNAL OF ANTIBIOTICS Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, taz Oct. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 5 327 27 2013 2014 2016 7 5 2013 2014 Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, tazobactam/piperacillin TAZ/PIPC, ceftazidime CAZ, cefepime

More information

CHEMOTHERAPY

CHEMOTHERAPY VOL.40 S-1 coagulase negative Staphylococcus sp, methicillin- resistant Staphylococcus aureus (MRSA), Enterococcus faecalis, Escherichia coli, Citrobacter freundii, Klebsiella pneumoniae, Enterobacter

More information

VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum

VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae methicillin-resistant Staphylococcus

More information

MIC MIC...

MIC MIC... 50 mg 10% 2.7.36 2.7.36 2.7.36... 1 1.6... 1 2.6... 3 3.6... 5 3.16... 5 3.26... 12 3.36... 16 4.6... 17 5.6... 19 6.6... 20 2.7.3.3.16-1 MIC... 9 2.7.3.3.16-2 MIC... 10 2.7.3.3.16-3 MIC E. coli... 11

More information

日本化学療法学会雑誌第58巻第4号

日本化学療法学会雑誌第58巻第4号 Escherichia coli Enterococcus faecalisstreptococcus agalactiae Klebsiella pneumoniae Staphylococcus epidermidis E. colie. faecalispseudomonas aeruginosa K. pneumoniae S. agalactiae E. coli E. coli μ p

More information

Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227,

Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227, Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227, P. putrefaciens 279 A. faecalis 120, A. ordrans 114

More information

dihydrostreptomycin(sm), sulfanilamide(sa), kanamycin(km), paromomycin(prm), fradiomycin(frm), ampicillin(apc), cephaloridine (CER), nalidixic acid(na

dihydrostreptomycin(sm), sulfanilamide(sa), kanamycin(km), paromomycin(prm), fradiomycin(frm), ampicillin(apc), cephaloridine (CER), nalidixic acid(na Key words: Shigella, Bacterial resistance against entibiotics. Distribution of R factors dihydrostreptomycin(sm), sulfanilamide(sa), kanamycin(km), paromomycin(prm), fradiomycin(frm), ampicillin(apc),

More information

VOL. 43 NO. 4

VOL. 43 NO. 4 VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics

More information

VOL. 33 S-5 CHEMO THERAPY Fig. 1 Chemical structure of HAPA-B 1-N-[ (2 S)-3-Amino-2-hydroxypropiony1]-4- O-(6-amino-6 - deoxy-ƒ -D- glucopyranosyl) -6

VOL. 33 S-5 CHEMO THERAPY Fig. 1 Chemical structure of HAPA-B 1-N-[ (2 S)-3-Amino-2-hydroxypropiony1]-4- O-(6-amino-6 - deoxy-ƒ -D- glucopyranosyl) -6 VOL. 33 S-5 CHEMO THERAPY Fig. 1 Chemical structure of HAPA-B 1-N-[ (2 S)-3-Amino-2-hydroxypropiony1]-4- O-(6-amino-6 - deoxy-ƒ -D- glucopyranosyl) -6- O-[3-deoxy-4 -C-methyl-3 -(methylamino) -ƒà-l- arabinopyranosyl]-2

More information

Table1MIC of BAY o 9867 against standard strains

Table1MIC of BAY o 9867 against standard strains Table1MIC of BAY o 9867 against standard strains Fig.2Cumulative and Distribution Curves of MIC (S.aureus 54 strains) 106cfu/ml Fig.3Correlogram of MIC (S.aureus 54 strains) CHEMOTHERAPY 451 Fig.4Cumulative

More information

第65回日本化学療法学会東日本支部総会 抄録

第65回日本化学療法学会東日本支部総会 抄録 鍵 76 Clostridioides difficile C. difficile 77 γ γ Mycobacterium avium 78 79 Clostridium difficile Treponema pallidum 80 81 82 in vitro in vitro 83 鍵 Treponema pallidum 84 Chlamydia trachomatis Mycoplasma

More information

Shigella flexneri 2a, Shigella flexneri 3a, Shigella sonnei, Salmonella, Salmonella arizonae, Citorobacter freundii, Enterobacter aerogenes, Enterobac

Shigella flexneri 2a, Shigella flexneri 3a, Shigella sonnei, Salmonella, Salmonella arizonae, Citorobacter freundii, Enterobacter aerogenes, Enterobac Key words: Edwardsiella tarda from Healthy Persons, H2S firoducinr. Escherichia coli Shigella flexneri 2a, Shigella flexneri 3a, Shigella sonnei, Salmonella, Salmonella arizonae, Citorobacter freundii,

More information

CHEMOTHERAPY APR. 1979

CHEMOTHERAPY APR. 1979 CHEMOTHERAPY APR. 1979 VOL.27 S-3 CHEMOTHERAPY CHEMOTHERAPY APR. 1070 Table 1 Comparison of antibiotic susceptibility of bacteria with the capacity to degrade cefotiam and other cephalosporine by /3-lactamase

More information

49619, H. influenzae ATCC49247, C. jejuni ATCC 33252, C. fetus ATCC15296, B. fragilis ATCC 25285, C. soldellii ATCC9714, P. rnagnus ATCC lin (ABPC), e

49619, H. influenzae ATCC49247, C. jejuni ATCC 33252, C. fetus ATCC15296, B. fragilis ATCC 25285, C. soldellii ATCC9714, P. rnagnus ATCC lin (ABPC), e Key words: MIC, agar dilution method, fastidious bacteria, Etes(R) 49619, H. influenzae ATCC49247, C. jejuni ATCC 33252, C. fetus ATCC15296, B. fragilis ATCC 25285, C. soldellii ATCC9714, P. rnagnus ATCC

More information